Wedbush Forecasts Stronger Earnings for Oruka Therapeutics

Key Points

• Wedbush has increased its Q3 2025 EPS estimate for Oruka Therapeutics to ($0.42), up from a previous estimate of ($0.51), maintaining an "Outperform" rating with a price target of $40.00.
• Other analysts have also shown optimism, with BTIG raising its price target from $44.00 to $56.00 and maintaining a "buy" rating.
• Oruka Therapeutics has experienced significant institutional investment, including a 464% increase by BNP Paribas Financial Markets during the second quarter.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Research analysts at Wedbush raised their Q3 2025 earnings per share (EPS) estimates for shares of Oruka Therapeutics in a research report issued on Wednesday, September 17th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($0.42) per share for the quarter, up from their previous forecast of ($0.51). Wedbush currently has a "Outperform" rating and a $40.00 target price on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.41) per share. Wedbush also issued estimates for Oruka Therapeutics' Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.70) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.89) EPS, FY2027 earnings at ($2.25) EPS, FY2028 earnings at ($2.98) EPS and FY2029 earnings at ($3.71) EPS.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.02.

A number of other research firms also recently weighed in on ORKA. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Monday, August 18th. BTIG Research upped their price target on Oruka Therapeutics from $44.00 to $56.00 and gave the stock a "buy" rating in a research report on Wednesday, September 17th. Finally, Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $42.00.

Oruka Therapeutics Trading Up 10.1%

Shares of NASDAQ:ORKA traded up $1.57 during trading on Monday, hitting $17.12. 566,650 shares of the company's stock traded hands, compared to its average volume of 292,321. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $31.13. The company has a 50-day moving average price of $14.86 and a 200-day moving average price of $12.27.

Institutional Trading of Oruka Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its stake in Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock valued at $31,000 after purchasing an additional 2,306 shares during the period. Bank of America Corp DE boosted its stake in Oruka Therapeutics by 287.6% in the 2nd quarter. Bank of America Corp DE now owns 18,849 shares of the company's stock valued at $211,000 after purchasing an additional 13,986 shares during the period. Cable Car Capital LP boosted its stake in Oruka Therapeutics by 33.3% in the 2nd quarter. Cable Car Capital LP now owns 600,000 shares of the company's stock valued at $6,726,000 after purchasing an additional 150,000 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Oruka Therapeutics in the 2nd quarter valued at $167,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Oruka Therapeutics by 22.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 52,747 shares of the company's stock valued at $591,000 after purchasing an additional 9,828 shares during the period. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.